Oncology ESMO 2025: ITM's Dr Andrew Cavey on next-gen RPTs At ESMO, pharmaphorum spoke with radiopharmaceutical biotech Isotope Technologies Munich SE (ITM) CEO Dr Andrew Cavey.
Oncology On nuclear medicine and oncology, SHINE Technologies Greg Piefer, founder and CEO of SHINE Technologies, discusses nuclear medicine and the role of radiopharmaceuticals in oncology.
Events Partner Content 4th Targeted Radiopharmaceuticals Summit Europe Join the primary assembly of pioneering TRP developers
Partner Content Partner Content SpectronRx Receives U.S. Nuclear Regulatory Commission Mater... Leading Radiopharma CDMO Opens Second Location
News UK says it has hit target on commercial trial set-up times The UK has made progress in its efforts to slash set-up times for clinical trials, one of the factors blamed for a decline in industry-backed studies.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
